Segment Information (Tables)

6 Months Ended

Jun. 30, 2025

Segment Reporting [Abstract]

Schedule of Income Statement Information

The following table provides selected income statement information for our single reportable segment (in thousands):

	For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2025			2024			2025			2024
Net loss before noncontrolling interest	$	(36,965	)	$	(38,466	)	$	(74,917	)	$	(73,799	)
Rental income		221			–			451			–
Depreciation and amortization		1,491			964			2,875			1,797
Equity-based compensation		6,540			7,808			12,957			15,489
Income tax (benefit) expense		848			(56	)		1,439			42
Interest expense		(1	)		(3	)		(1	)		(5	)
Interest income		3,593			4,537			7,620			9,380

Schedule of Significant Expense Reported to the Chief Operating Decision Maker

The following table provides significant expense categories that are regularly reported to the CODM (in thousands):

	For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2025			2024			2025			2024
Revenue	$	221		$	–		$	451		$	–
Clinical trial expense		7,188			10,619			14,711			18,927
Cash compensation		13,811			11,059			27,064			21,669
Cash operating expenses		11,595			12,325			24,739			24,701
Other segment items (1)		4,592			4,463			8,854			8,502
Net loss before noncontrolling interest	$	(36,965	)	$	(38,466	)	$	(74,917	)	$	(73,799	)

(1)Other segment items primarily include interest income, equity-based compensation and depreciation.